Physician profile
Peter Hale
NPI 1376905497
$9,076.08
in general payments reported to CMS, 2019-2025
66 companies · $3,223 in 2025
The $3,223 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.76 · 2022: $592 · 2023: $2,309 · 2024: $2,906 · 2025: $3,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,038 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,037.58 |
| Education | $399.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $881.29 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $795.44 | 2022-2025 | Imfinzi, Lynparza, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $523.21 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Janssen Biotech, INC. | $457.60 | 2023-2025 | Erleada, Darzalex, Akeega |
| Abbvie INC. | $443.64 | 2019-2025 | |
| Daiichi Sankyo INC. | $384.88 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Novartis Pharmaceuticals Corporation | $359.19 | 2022-2025 | |
| Celgene Corporation | $334.89 | 2022-2025 | Reblozyl, Pomalyst, Breyanzi |
| Merck Sharp & Dohme LLC | $332.93 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Genzyme Corporation | $297.21 | 2022-2025 | |
| Astellas Pharma US INC | $293.61 | 2022-2025 | Padcev, Xtandi, Vyloy |
| Genentech USA, INC. | $283.11 | 2023-2025 | Phesgo, Perjeta, Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $252.73 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Glaxosmithkline, LLC. | $224.76 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Eisai INC. | $219.07 | 2022-2025 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $192.27 | 2022-2025 | Jakafi, Monjuvi |
| Tersera Therapeutics LLC | $186.55 | 2023-2025 | Zoladex, Quzyttir |
| Lilly USA, LLC | $169.12 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Sobi, INC | $157.72 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $156.96 | 2024-2025 | |
| Blueprint Medicines Corporation | $147.82 | 2023-2025 | Ayvakit |
| Amgen INC. | $130.47 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.17 | 2022-2024 | Gilotrif |
| Puma Biotechnology, INC. | $106.54 | 2023-2025 | |
| Beone Medicines USA, INC. | $102.60 | 2025 | Brukinsa, Tevimbra |
| Servier Pharmaceuticals LLC | $83.54 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $78.71 | 2023-2025 | |
| Dendreon Pharmaceuticals LLC | $69.78 | 2024-2025 | Provenge |
| Sumitomo Pharma America, INC. | $66.95 | 2023-2025 | Orgovyx |
| Seagen INC. | $65.40 | 2022-2023 | Adcetris |
| Exelixis INC. | $63.84 | 2024 | Cabometyx |
| Emd Serono, INC. | $60.29 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.09 | 2022-2024 | |
| Iovance Biotherapeutics, INC. | $55.61 | 2025 | Amtagvi |
| Array Biopharma INC | $50.40 | 2023-2025 | Mektovi, Xalkori, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $45.45 | 2023 | Libtayo |
| Coherus Oncology, INC. | $44.68 | 2023-2024 | |
| Cti Biopharma Corp. | $44.38 | 2022-2023 | Vonjo |
| Syndax Pharmaceuticals, INC. | $44.05 | 2025 | Revuforj |
| Pharmacosmos Therapeutics INC. | $43.36 | 2023-2024 | Monoferric |
| Adc Therapeutics America, INC. | $40.14 | 2025 | |
| Medtronic, INC. | $39.81 | 2022-2025 | Synchromedii |
| Geron Corporation | $38.15 | 2025 | Rytelo |
| Karyopharm Therapeutics INC. | $37.75 | 2023 | Xpovio |
| Kite Pharma, INC. | $35.49 | 2023 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $35.42 | 2022-2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $33.47 | 2024 | Tavalisse, Rezlidhia |
| Adaptive Biotechnologies Corporation | $32.85 | 2025 | Clonoseq |
| Azurity Pharmaceuticals, INC. | $29.42 | 2025 | Danziten |
| Fresenius Kabi USA, LLC | $29.21 | 2023-2025 | Stimufend |
| Alexion Pharmaceuticals, INC. | $26.72 | 2025 | Koselugo |
| Beigene USA, INC. | $24.57 | 2024 | Brukinsa |
| Stemline Therapeutics INC. | $24.34 | 2024 | Orserdu |
| Pharmaessentia USA Corporation | $22.99 | 2024 | Besremi |
| Novocure INC. | $22.29 | 2025 | Optune Lua (Novottf-200t) |
| Springworks Therapeutics, INC. | $20.40 | 2024 | Ogsiveo |
| Ipsen Biopharmaceuticals, INC | $18.95 | 2024 | Onivyde, Somatuline Depot |
| Sirtex Medical INC | $18.35 | 2023 | Sir-Spheres Microspheres |
| Mirati Therapeutics, INC. | $17.55 | 2023 | Krazati |
| Genmab U.S., INC. | $17.33 | 2025 | Epkinly |
| Spectrum Pharmaceuticals INC. | $17.11 | 2024 | Rolvedon |
| Deciphera Pharmaceuticals INC. | $17.02 | 2023 | Qinlock |
| Sun Pharmaceutical Industries INC. | $15.85 | 2025 | |
| Recordati_rare_diseases_inc. | $14.84 | 2025 | Enjaymo |
| Morphosys, US INC. | $13.31 | 2023 | Monjuvi |
| Apellis Pharmaceuticals, INC. | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.